India Benign Prostatic Hyperplasia Treatment Market Research Report By Therapeutic Class (Alpha Blockers, 5- Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others) and By Therapy (Mono Drug Therapy, Combination Drug Therapy)- Forecast to 2035

India Benign Prostatic Hyperplasia Treatment Market Overview

As per MRFR analysis, the India Benign Prostatic Hyperplasia Treatment Market Size was estimated at 472.04 (USD Million) in 2023. The India Benign Prostatic Hyperplasia Treatment Market Industry is expected to grow from 498(USD Million) in 2024 to 1,090 (USD Million) by 2035. The India Benign Prostatic Hyperplasia Treatment Market CAGR (growth rate) is expected to be around 7.381% during the forecast period (2025 - 2035).

Key India Benign Prostatic Hyperplasia Treatment Market Trends Highlighted

The India Benign Prostatic Hyperplasia (BPH) treatment market is experiencing significant growth driven by an increasing prevalence of prostate-related issues among the aging male population. The government of India reports a rising number of geriatric individuals, which serves as a key market driver, considering the direct correlation between age and the likelihood of developing BPH. Lifestyle changes, including diet and lack of physical activity, further exacerbate these health concerns, pushing many towards seeking treatment options. Recent advancements in medical technology, such as minimally invasive surgical techniques and new pharmacological treatments, present substantial opportunities for healthcare providers and pharmaceutical companies to explore in this evolving market.

Increased awareness of BPH and its treatment options through educational campaigns and healthcare initiatives has significantly contributed to the demand for these services. Additionally, the rise of telemedicine in rural and urban areas allows patients greater access to BPH specialists and treatments, making healthcare more accessible and expanding the market potential. Moreover, recent trends indicate a shift towards holistic approaches for managing BPH, combining traditional therapeutic regimens with lifestyle modifications that focus on overall well-being. Herbal supplements and dietary changes are increasingly being integrated into treatment plans.

This holistic view aligns with cultural practices in India, where natural remedies hold significant value. As the urban population grows and healthcare infrastructure improves, the market for BPH treatment is set to expand further, highlighting a clear opportunity for new players to invest and innovate within the sector.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

India Benign Prostatic Hyperplasia Treatment Market Drivers

Aging Population in India

The growing ageing population is the primary driver of the India Benign Prostatic Hyperplasia Treatment Market. The Ministry of Statistics and Program Implementation projects that by 2050, the proportion of people 60 and older will increase from 8.6% in 2011 to 19.7%. The increasing number of senior people will probably increase the need for efficient treatment alternatives since the prevalence of benign prostatic hyperplasia (BPH) rises with age. This tendency has been acknowledged by organisations like the All-India Institute of Medical Sciences, which shows that more than 50% of men over 60 suffer from BPH. 

As more people look for treatment options to control their diseases, this demographic transition is expected to propel the industry ahead substantially. This will present pharmaceutical businesses and healthcare professionals with plenty of opportunities to create customised medicines and procedures.

Rising Awareness and Education About Prostate Health

There has been a considerable rise in awareness and education regarding prostate health among men in India, spurred by educational initiatives conducted by non-profit organizations and medical associations. The Indian Urological Association has been actively promoting awareness campaigns to educate the public about benign prostatic hyperplasia, leading to earlier diagnosis and treatment. Studies suggest that awareness can lead to a potential increase in the number of diagnosed cases of BPH, which can be projected to grow by approximately 30% over the next decade.

Such proactive educational efforts are essential to reducing stigma and encouraging men to seek medical care, thereby boosting the India Benign Prostatic Hyperplasia Treatment Market.

Advancements in Treatment Technologies

Significant advancements in treatment technologies for benign prostatic hyperplasia are driving market growth in India. Innovations like minimally invasive surgical techniques and new pharmacological therapies have improved patient outcomes and decreased recovery times. The Urology Society of India has noted a growing trend in the adoption of these advanced technologies, with procedures like holmium laser enucleation of the prostate becoming more commonplace.

The increased efficacy and reduced side effects of these treatments are appealing to patients, resulting in higher treatment rates. As a result, organizations focusing on research and clinical trials are expected to spur further development in this field, illustrating a promising future for the India Benign Prostatic Hyperplasia Treatment Market.

Government Initiatives and Health Policies

The Indian government has been implementing various health initiatives to improve healthcare access and affordability for chronic conditions, including benign prostatic hyperplasia. Programs like the Ayushman Bharat scheme aim to provide insurance coverage to economically vulnerable populations, which indirectly drives the market by increasing patient footfall in healthcare facilities for BPH diagnosis and treatment. The National Health Policy 2017 emphasizes the importance of early detection and treatment of non-communicable diseases, including prostate-related disorders.

These findings suggest that government initiatives can significantly enhance treatment accessibility, further stimulating the growth of the India Benign Prostatic Hyperplasia Treatment Market.

India Benign Prostatic Hyperplasia Treatment Market Segment Insights

Benign Prostatic Hyperplasia Treatment Market Therapeutic Class Insights

The India Benign Prostatic Hyperplasia Treatment Market is witnessing significant growth, particularly in the Therapeutic Class segment, which plays a pivotal role in addressing this common condition among men. The segment consists of various classes of medications, including Alpha Blockers, 5-Alpha Reductase Inhibitors, and Phosphodiesterase-5 Inhibitors, along with other treatments. Alpha Blockers remain a popular choice due to their efficacy in relaxing muscle fibers in the prostate, thereby improving urinary flow and reducing symptoms associated with benign prostatic hyperplasia. Their rapid onset of action and favorable safety profile contribute to their dominance in the market.

5-Alpha Reductase Inhibitors, on the other hand, are significant for their ability to address the underlying causes of the condition by reducing prostate size over time. This class of drugs is particularly important for patients with larger prostate volumes, as they not only alleviate symptoms but also lower the risk of surgical intervention in the long term. Phosphodiesterase-5 Inhibitors represent a newer option in the treatment landscape, offering additional benefits for patients who may also have erectile dysfunction, thus enhancing overall quality of life.

The segmentation of the India Benign Prostatic Hyperplasia Treatment Market highlights the diverse therapeutic options available to healthcare providers, allowing for personalized treatment plans based on patient needs. With an increasing prevalence of benign prostatic hyperplasia due to the aging male population in India, there is a growing demand for effective treatment options within this segment. The availability of a variety of therapeutic classes provides ample opportunities for pharmaceutical companies to innovate and enhance their product offerings. Such diversity not only meets the specific needs of patients but also gives healthcare professionals the flexibility to tailor treatments that can improve patient adherence and satisfaction. 

Market drivers include the rising awareness of benign prostatic hyperplasia and the expansion of healthcare infrastructure in India. Additionally, the emphasis on early diagnosis and treatment among healthcare practitioners is further contributing to the growth of this segment. Challenges such as medication adherence and the need for ongoing patient education about treatment options remain pertinent but present opportunities for improvements through better communication strategies and support programs. Overall, the Therapeutic Class segment within the India Benign Prostatic Hyperplasia Treatment Market is characterized by a mix of established and emerging treatment options, which will likely continue to evolve to meet the needs of patients and healthcare providers alike.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Benign Prostatic Hyperplasia Treatment Market Therapy Insights

The India Benign Prostatic Hyperplasia Treatment Market, particularly in the Therapy segment, has seen notable advancements and diversification in recent years. The market encompasses various treatment methodologies designed to alleviate the symptoms associated with benign prostatic hyperplasia. Mono Drug Therapy remains a significant approach, often preferred for its simplicity and effectiveness for many patients. It involves a single medication aimed at reducing prostate size or easing urinary symptoms, thereby improving patient compliance. On the other hand, Combination Drug Therapy is gaining traction due to its potential to provide a more comprehensive treatment solution.

By combining different pharmacological agents, this therapy can target multiple pathways of the disease process, potentially leading to improved outcomes for patients suffering from this condition. The increasing prevalence of benign prostatic hyperplasia among the aging male population in India serves as a catalyst for the growth of these therapies. 

Furthermore, rising awareness, advancements in drug formulation, and the healthcare infrastructure in India contribute to market evolution. Each therapy type plays a crucial role in shaping treatment protocols, catering to a vast patient demographic and addressing the varying degrees of severity of the condition.

India Benign Prostatic Hyperplasia Treatment Market Key Players and Competitive Insights:

The India Benign Prostatic Hyperplasia Treatment Market is experiencing considerable attention due to the rising prevalence of prostate-related disorders among the aging male population. Factors such as increasing awareness about prostate health, advancements in treatment methodologies, and a growing pool of healthcare practitioners adopting innovative therapies contribute to a competitive landscape in this market. The emphasis on effective treatments has led various pharmaceutical companies to enhance their product portfolios and establish a stronger market presence. 

Companies are not only focused on developing new medications but are also exploring opportunities to expand their reach through strategic alliances, partnerships, and collaborations with healthcare providers, thereby creating a dynamic competitive environment.Sun Pharmaceutical Industries has made significant strides in the Indian Benign Prostatic Hyperplasia Treatment Market, positioning itself as a key player in the sector. The company leverages its extensive experience in research and development, along with a robust manufacturing infrastructure, to deliver high-quality therapeutic solutions specifically tailored to prostate health. With a strong distribution network, Sun Pharmaceutical Industries ensures that its products are accessible to healthcare professionals and patients across India, enhancing its market presence. 

Additionally, the company is recognized for its commitment to addressing the needs of its consumers by continuously investing in innovative treatment options and maintaining compliance with regulatory standards, thereby demonstrating its strength within this specialized market.

Bayer has also established a prominent foothold in the India Benign Prostatic Hyperplasia Treatment Market, focusing on delivering effective solutions that cater to the unique needs of patients suffering from this condition. The company provides a range of medications and therapies designed specifically for prostate health, emphasizing research-driven innovations. Bayer's strategic market presence is enhanced through partnerships and collaborations with healthcare providers and drug distributors, ensuring that its products reach a broad audience. Furthermore, the company has a strong commitment to patient education, helping to raise awareness about prostate health and related treatment options in India. 

Bayer’s strengths are coupled with a focus on continuous research and further development around its key products, making it a formidable player in the Indian market, supported by its history of successful mergers and acquisitions that expand its capabilities and enhance its product offerings in the therapeutic space.

Key Companies in the India Benign Prostatic Hyperplasia Treatment Market Include:

• Sun Pharmaceutical Industries


• Bayer


• GlaxoSmithKline


• Novartis


• AstraZeneca


• Merck & Co


• Hetero Drugs


• Cipla


• Johnson & Johnson


• Wockhardt


• Teva Pharmaceutical Industries


• AbbVie


• Hospira


• Pfizer


• Eli Lilly and Company

India Benign Prostatic Hyperplasia Treatment Market Industry Developments

The India Benign Prostatic Hyperplasia Treatment Market has witnessed significant developments recently. In August 2023, Sun Pharmaceutical Industries launched a new formulation aimed at improving patient adherence and outcomes in the management of benign prostatic hyperplasia (BPH). Meanwhile, Bayer announced in September 2023 advancements in their drug pipeline targeting BPH, strengthening their position in the market. Growth has been observable in the sector, with the market valuation reportedly increasing due to rising prevalence rates and an aging population. 

Companies like GlaxoSmithKline and Merck and Co. have focused on enhancing their Research and Development initiatives related to BPH treatments over the last couple of years, with notable investments in 2022 leading to innovative product launches. On the mergers and acquisitions front, in March 2023, Cipla confirmed the acquisition of a regional player specializing in urological treatments, expanding its footprint in the market. The competitive landscape remains dynamic, with major players such as Novartis and AstraZeneca actively pursuing collaborations and studies aimed at improving therapeutic options for BPH, reflecting a growing commitment to addressing this common condition affecting men in India.

India Benign Prostatic Hyperplasia Treatment Market Segmentation Insights

Benign Prostatic Hyperplasia Treatment Market Therapeutic Class Outlook

• Alpha Blockers


• 5- Alpha Reductase Inhibitors


• Phosphodiesterase-5 Inhibitors


• Others

Benign Prostatic Hyperplasia Treatment Market Therapy Outlook

• Mono Drug Therapy


• Combination Drug Therapy

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	472.04(USD Million)
MARKET SIZE 2024	498.0(USD Million)
MARKET SIZE 2035	1090.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.381% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Sun Pharmaceutical Industries, Bayer, GlaxoSmithKline, Novartis, AstraZeneca, Merck & Co, Hetero Drugs, Cipla, Johnson & Johnson, Wockhardt, Teva Pharmaceutical Industries, AbbVie, Hospira, Pfizer, Eli Lilly and Company
SEGMENTS COVERED	Therapeutic Class, Therapy
KEY MARKET OPPORTUNITIES	Growing elderly population, Increased awareness and diagnosis, Advancements in minimally invasive treatments, Expansion of telemedicine services, Rising prevalence of comorbidities
KEY MARKET DYNAMICS	Increasing aging population, Rising prevalence of BPH, Advancements in treatment technologies, Growing awareness and education, Expanding healthcare infrastructure
COUNTRIES COVERED	India